10x Genomics (NASDAQ: TXG) reported Q3 EPS of ($0.15), $0.05 better than the analyst estimate of ($0.20). Revenue for the quarter came in at $125.3 million versus the consensus estimate of $124.69 million.

GUIDANCE:

10x Genomics sees Q4 2021 revenue of $490-500 million, versus the consensus of $489.77 million.

For earnings history and earnings-related data on 10x Genomics (TXG) click here.